Table 1.

Characteristics of retrospective studies

Ref.	Country	Year	n	Group 1	Group 2	Study outcome(s)	Comments
Ammori et al[5]	United States	2007	184	Strict glucose control (BG < 150 mg/dL)	Poor Glucose control (BG ≥ 150 mg/dL)	Mortality Infection rate
Chung et al[25]	South Korea	2014	211	BG decline during the Neohepatic Phase (Yes)	BG decline during the Neohepatic Phase (No)	Mortality, length of ICU stay, early allograft dysfunction, MELD Score recovery	Outcomes were assessed relative to the drop in hyperglycemia after the neohepatic phase
Gelley et al[21]	Hungary	2011	310	De novo diabetes	Control	HepC recurrence and association with NODAT
Hartog et al[23]	United Kingdom	2014	430	DBD	DCD	NODAT
Keegan et al[17]	United States	2010	161 (158 were available for analysis)	Pre-protocol	Protocol	Mortality Morbidity Graft function
Linder et al[18]	United States	2016	114	PTDM	Non-PTDM	PTDM	BPAR, allograft failure, death, CMV infection are additional endpoints
Park et al[4]	United States/Taiwan	2009	680	SSI (Yes)	SSI (No)	SSI
Trail et al[20]	United States	1996	497	PTDM	Case-control	PTDM morbidity	PTDM leading to infections and graft rejection
Wallia et al[1]	United States	2010	144	BG > 200 mg/dL	BG < 200 mg/dL	Graft rejection, infection, and re-hospitalization	Graft survival and prolonged ventilation
Wallia et al[19]	United States	2011	73	Glucose management service	Non-Glucose Management Service	Graft rejection, infection, and re-hospitalization	Graft survival and prolonged ventilation
Yoo et al[6]	South Korea	2016	304	Normoglycemia (BG: 80-200 mg/dL)	Mild hyperglycemia (BG: 200-250 mg/dL)	AKI	Group 3: Moderate hyperglycemia (250-300 mg/dL) Group 4: Severe hyperglycemia (> 300 mg/dL)

DBD: Donated after brain death; PTDM: Post-transplant diabetes mellitus; Non-PTDM: Transplant diabetes mellitus free; DCD: Donated after circulatory death; NODAT: New onset diabetes after transplantation; AKI: Acute kidney injury.